1McConnell JD,Reginald B,Waish P,et al.The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia.Finasteride Long-Term Efficacy and Safety study Group[J].N Engl J Med,1998,338(9):557-563.
2Steers WD.5 alpha-reductase activity in the prostate[J].Urology,2001,58(suppl 6A):17-24.
3Bartsch G,Rittmaster RS,Klocker H.Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia[J].world J Urol,2002,19(6):413-425.
4MeConnell JD.Androgen suppression in the management of benign prostatic hyperplasia[M]//Lepor H eds.Prostatic Diseases[J].Philadelphia:Saunders,2001:308-320.
5Stuart JD,Lee FW,Simpson-Nod D,et al.Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5 alpha-reductases:determinantsfor different in vivo activities of GI198745 and finasteride in the rat[J].Biochem Pharmacol,2001,62(7):933-942.
6Andriole GL,Kirby R.Safery and tolerability of the dual 5α-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia[J].Eur Urol,2003,44(1):82-83.
7Andriole G,Ray P,Gumphrey P,et al.The impact of dutasteride,a novel 5 alpha-reductase inhibitor on serum and intraprostatic anddrogens.Proceedings of the 2nd Wodd Congress on Men's Health[C].2002:30.
9Clark RV.Marked suppression of dihydrotestosterone (DHT)by dutasteride has no adverse effect on spermatogenesis in healthy men[J].Br J Urol,2002,90(suppl 2):14.
10Roehrbom CG,Boyle P.Efficacy and safety of a dual inhibitor of 5 alpha reductase type 1 and 2(dutasteride)in men with benign prostatic hyperplasia[J].Urology,2002,60(3):434-441.
2Rhodes PR, Krogh RH, Bruskewitz RC. Impact of drug therapy on benign prostatic hyperplasia-specifie quality of life. Urology 1999; 53(2): 1090-1098.
3Hieble JP, Bylund DB, Clarke DE, et al. International union of pharmacology X.recommendation for nomenclature of α 1-adrenceptors consensus update. Pharmacol Rev 1995; 47(2): 267-269.
4Nasu K, Moriyama N, Fukasawa R, et al. Quantification and distribution of α 1-adrenceptor subtype mRNAs in human proximal urethra. Br J Phramacol 1998; 123 (7):1289-1293.
5Takei R, Ikegaki I, Shibata K, et al. Naftopidil, a novel α1-adrenceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human α 1-adrenceptors. Jpn J Phamacol 1997;79(4): 447-454.
6Niebch G, Locher M, Borbe HO. Metabolic fate of the novel antihypertensive drug naftopidil. Arzneimittelforschung 1991; 41(10): 1027-1032.
7Takagi N, Ishii M, Takeda K, et al. Pharmacokinetics of naftopidil (KT-611) in hypertensive patients with renal impairment or normal renal function. J Clin Ther Med 1992; 8(3): 109-122.
8Farthing MJ, Alstead EM, Abrams SM, et al, Pharmacokinetics of naftopidil, a novel anti-hypertensive drug,in patients with hepatic dysfunction. Postgrad Med J 1994; 70 (2):363-366.
9Yasuda K, Yamanishi T, Tojo M, et al. Effrct of naftopidil on urethral obstruction in benigh prostatic hyperplasia;assessment by urodynamic studies. Prostate 1994; 25(1): 46-52.
